Truffle Capital & The Institut Pasteur Create SpikImm to Develop Monoclonal Antibodies as an Innovative Treatment For Covid-19
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210505005708/en/
Monoclonal antibody therapy is one of the most innovative ways currently available to treat Covid-19 patients and prevent severe forms of the disease from developing. This immunotherapy offers several therapeutic advantages which have already been proven in clinical trials. Antibodies developed by SpikImm have been generated in the laboratory of Humoral Immunology at the Institut Pasteur through an innovative process enabling the screening and selection of human SARS-CoV-2 neutralizing antibodies. An international patent application has been filed by the Institut Pasteur.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Truffle Capital Reports Outstanding 2020 Stock Market Performance for Its Listed BioMedTech Portfolio Companies
February 1, 2021 GMT
Truffle Capital:
1. Three leading BioMedTech companies, Founded or Co-Founded and Supported by Truffle Capital since Their Inception, Generate Outstanding Performance in 2020
As of today,
Carbios (EPA: ALCRB) and
Carmat (EPA: ALCAR), are collectively capitalizing €1.3 billion (497, 443 and 379 M€ respectively) and ranking among the best 2020 stock performers listed on Euronext Paris (including
Carbios at the 1 st position; among the companies capitalizing between €200 million and 2 billion; see table below). These three companies are all developing radical innovations aiming at revolutionizing the medical sector or the protection of the environment.